ArticleInternational journal of molecular sciences2026
Novel 3-Amino-2-methylquinazolinone NF-κB Inhibitors: Synthesis and Potential Anti-Inflammatory Function.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthesis of Quinazoline Derivatives and Mechanistic Approaches in Lung and Breast Cancers.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The canonical NF-κB pathway is a major regulator of inflammatory responses, and its persistent activation has been linked to chronic inflammatory diseases and cancer development. It is therefore important to develop effective NF-κB inhibitors that can potentially be utilized in further preclinical studies. In this study, we have synthesized various quinazolinone compounds using novel methodologies. We specifically utilized a two-step protocol comparing an established protocol to a modified alternative procedure and then successfully established a novel one-pot multi-component reaction. All quinazolinones were tested based on their capacity to inhibit tumor necrosis factor-induced NF-κB activation using a commercial transgenic HeLa reporter cell-line. Among the eighteen molecules tested, two compounds affected the NF-κB-dependent luciferase activity, the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.